> top > projects > Inflammaging > docs > PubMed:21658240 > annotations
Inflammaging  

PubMed:21658240 JSONTXT 9 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
T1 0-221 Sentence denotes Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study.
T1 0-221 Sentence denotes Enteral nutrition with eicosapentaenoic acid, γ-linolenic acid and antioxidants in the early treatment of sepsis: results from a multicenter, prospective, randomized, double-blinded, controlled study: the INTERSEPT study.
T2 222-235 Sentence denotes INTRODUCTION:
T2 222-235 Sentence denotes INTRODUCTION:
T3 236-391 Sentence denotes Enteral nutrition (EN) with eicosapentaenoic acid (EPA)/γ-linolenic acid (GLA) is recommended for mechanically ventilated patients with severe lung injury.
T3 236-391 Sentence denotes Enteral nutrition (EN) with eicosapentaenoic acid (EPA)/γ-linolenic acid (GLA) is recommended for mechanically ventilated patients with severe lung injury.
T4 392-615 Sentence denotes EPA/GLA has anti-inflammatory benefits, as evidenced by its association with reduction in pulmonary inflammation, improvement in oxygenation and improved clinical outcomes in patients with severe forms of acute lung injury.
T4 392-615 Sentence denotes EPA/GLA has anti-inflammatory benefits, as evidenced by its association with reduction in pulmonary inflammation, improvement in oxygenation and improved clinical outcomes in patients with severe forms of acute lung injury.
T5 616-1135 Sentence denotes This study was a prospective, multicenter, randomized, double-blinded, controlled trial designed to investigate whether EPA/GLA could have an effective role in the treatment of patients with early sepsis (systemic inflammatory response syndrome with confirmed or presumed infection and without any organ dysfunction) by reducing the progression of the disease to severe sepsis (sepsis associated with at least one organ failure) or septic shock (sepsis associated with hypotension despite adequate fluid resuscitation).
T5 616-1135 Sentence denotes This study was a prospective, multicenter, randomized, double-blinded, controlled trial designed to investigate whether EPA/GLA could have an effective role in the treatment of patients with early sepsis (systemic inflammatory response syndrome with confirmed or presumed infection and without any organ dysfunction) by reducing the progression of the disease to severe sepsis (sepsis associated with at least one organ failure) or septic shock (sepsis associated with hypotension despite adequate fluid resuscitation).
T6 1136-1315 Sentence denotes Secondary outcomes included the development of individual organ failure, increased ICU and hospital length of stay, need for mechanical ventilation and 28-day all-cause mortality.
T6 1136-1315 Sentence denotes Secondary outcomes included the development of individual organ failure, increased ICU and hospital length of stay, need for mechanical ventilation and 28-day all-cause mortality.
T7 1316-1324 Sentence denotes METHODS:
T7 1316-1324 Sentence denotes METHODS:
T8 1325-1504 Sentence denotes Randomization was concealed, and patients were allocated to receive, for seven days, either an EPA/GLA diet or an isocaloric, isonitrogenous control diet not enhanced with lipids.
T8 1325-1504 Sentence denotes Randomization was concealed, and patients were allocated to receive, for seven days, either an EPA/GLA diet or an isocaloric, isonitrogenous control diet not enhanced with lipids.
T9 1505-1595 Sentence denotes Patients were continuously tube-fed at a minimum of 75% of basal energy expenditure × 1.3.
T9 1505-1595 Sentence denotes Patients were continuously tube-fed at a minimum of 75% of basal energy expenditure × 1.3.
T10 1596-1721 Sentence denotes To evaluate the progression to severe sepsis and/or septic shock, daily screening for individual organ failure was performed.
T10 1596-1721 Sentence denotes To evaluate the progression to severe sepsis and/or septic shock, daily screening for individual organ failure was performed.
T11 1722-1791 Sentence denotes All clinical outcomes were recorded during a 28-day follow-up period.
T11 1722-1791 Sentence denotes All clinical outcomes were recorded during a 28-day follow-up period.
T12 1792-1800 Sentence denotes RESULTS:
T12 1792-1800 Sentence denotes RESULTS:
T13 1801-1924 Sentence denotes A total of 115 patients in the early stages of sepsis requiring EN were included, among whom 106 were considered evaluable.
T13 1801-1924 Sentence denotes A total of 115 patients in the early stages of sepsis requiring EN were included, among whom 106 were considered evaluable.
T14 1925-2240 Sentence denotes Intention-to-treat (ITT) analysis demonstrated that patients fed the EPA/GLA diet developed less severe sepsis and/or septic shock than patients fed the control diet (26.3% versus 50%, respectively; P = 0.0259), with similar results observed for the evaluable patients (26.4% versus 50.9% respectively; P = 0.0217).
T14 1925-2240 Sentence denotes Intention-to-treat (ITT) analysis demonstrated that patients fed the EPA/GLA diet developed less severe sepsis and/or septic shock than patients fed the control diet (26.3% versus 50%, respectively; P = 0.0259), with similar results observed for the evaluable patients (26.4% versus 50.9% respectively; P = 0.0217).
T15 2241-2487 Sentence denotes The ITT analysis demonstrated that patients in the study group developed cardiovascular failure (36.2% versus 21%, respectively; P = 0.0381) and respiratory failure (39.6% versus 24.6%, respectively; P = 0.0362) less often than the control group.
T15 2241-2487 Sentence denotes The ITT analysis demonstrated that patients in the study group developed cardiovascular failure (36.2% versus 21%, respectively; P = 0.0381) and respiratory failure (39.6% versus 24.6%, respectively; P = 0.0362) less often than the control group.
T16 2488-2707 Sentence denotes Similarly, when considering only the evaluable patients, fewer patients developed cardiovascular failure (20.7% versus 37.7%, respectively; P = 0.03) and respiratory failure (26.4% versus 39.6%, respectively; P = 0.04).
T16 2488-2707 Sentence denotes Similarly, when considering only the evaluable patients, fewer patients developed cardiovascular failure (20.7% versus 37.7%, respectively; P = 0.03) and respiratory failure (26.4% versus 39.6%, respectively; P = 0.04).
T17 2708-2847 Sentence denotes The percentage of patients fed the EPA/GLA diet requiring invasive mechanical ventilation was reduced compared with controls (ITT patients:
T17 2708-2847 Sentence denotes The percentage of patients fed the EPA/GLA diet requiring invasive mechanical ventilation was reduced compared with controls (ITT patients:
T18 2848-2912 Sentence denotes 18.9% versus 33.9%, respectively; P = 0.394; evaluable patients:
T18 2848-2912 Sentence denotes 18.9% versus 33.9%, respectively; P = 0.394; evaluable patients:
T19 2913-2958 Sentence denotes 17.5% versus 34.5%, respectively; P = 0.295).
T19 2913-2958 Sentence denotes 17.5% versus 34.5%, respectively; P = 0.295).
T20 2959-3073 Sentence denotes Patients nourished with the EPA/GLA diet remained in the ICU fewer days than the control population (ITT patients:
T20 2959-3073 Sentence denotes Patients nourished with the EPA/GLA diet remained in the ICU fewer days than the control population (ITT patients:
T21 3074-3165 Sentence denotes 21.1 ICU-free days versus 14.7 ICU-free days, respectively; P < 0.0001; evaluable patients:
T21 3074-3165 Sentence denotes 21.1 ICU-free days versus 14.7 ICU-free days, respectively; P < 0.0001; evaluable patients:
T22 3166-3283 Sentence denotes 20.8 ICU-free days versus 14.3 ICU-free days, respectively; P < 0.0001) and fewer days at the hospital (ITT patients:
T22 3166-3283 Sentence denotes 20.8 ICU-free days versus 14.3 ICU-free days, respectively; P < 0.0001) and fewer days at the hospital (ITT patients:
T23 3284-3385 Sentence denotes 19.5 hospital-free days versus 10.3 hospital-free days, respectively; P < 0.0001; evaluable patients:
T23 3284-3385 Sentence denotes 19.5 hospital-free days versus 10.3 hospital-free days, respectively; P < 0.0001; evaluable patients:
T24 3386-3500 Sentence denotes 19.1 hospital-free days versus 10.2 hospital-free days, respectively; P < 0.001) (all numbers expressed as means).
T24 3386-3500 Sentence denotes 19.1 hospital-free days versus 10.2 hospital-free days, respectively; P < 0.001) (all numbers expressed as means).
T25 3501-3586 Sentence denotes No significant differences in 28-day all-cause mortality were observed (ITT patients:
T25 3501-3586 Sentence denotes No significant differences in 28-day all-cause mortality were observed (ITT patients:
T26 3587-3667 Sentence denotes 26.2% EPA/GLA diet versus 27.6% control diet, respectively; P = 0.72; evaluable:
T26 3587-3667 Sentence denotes 26.2% EPA/GLA diet versus 27.6% control diet, respectively; P = 0.72; evaluable:
T27 3668-3737 Sentence denotes 26.4 EPA/GLA diet versus 30.18 control diet, respectively; P = 0.79).
T27 3668-3737 Sentence denotes 26.4 EPA/GLA diet versus 30.18 control diet, respectively; P = 0.79).
T28 3738-3750 Sentence denotes CONCLUSIONS:
T28 3738-3750 Sentence denotes CONCLUSIONS:
T29 3751-4069 Sentence denotes These data suggest that EPA/GLA may play a beneficial role in the treatment of enterally fed patients in the early stages of sepsis without associated organ dysfunction by contributing to slowing the progression of sepsis-related organ dysfunction, especially with regard to cardiovascular and respiratory dysfunction.
T29 3751-4069 Sentence denotes These data suggest that EPA/GLA may play a beneficial role in the treatment of enterally fed patients in the early stages of sepsis without associated organ dysfunction by contributing to slowing the progression of sepsis-related organ dysfunction, especially with regard to cardiovascular and respiratory dysfunction.
T30 4070-4089 Sentence denotes TRIAL REGISTRATION:
T30 4070-4089 Sentence denotes TRIAL REGISTRATION:
T31 4090-4122 Sentence denotes ClinicalTrials.gov: NCT00981877.
T31 4090-4122 Sentence denotes ClinicalTrials.gov: NCT00981877.